Trials / Conditions / BRAF V600K Mutation Present
BRAF V600K Mutation Present
3 registered clinical trials studyying BRAF V600K Mutation Present — 1 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Recruiting | Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer NCT03975231 | City of Hope Medical Center | Phase 1 |
| Terminated | Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are NCT02097225 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is NCT01940809 | National Cancer Institute (NCI) | Phase 1 |